Ardelyx Data on Phosphate Inhibitor to be Presented at NKF Meeting

Event summary

  • Ardelyx will present data at the National Kidney Foundation’s (NKF) Spring Clinical Meetings on May 7-10, 2026, regarding the long-term impact of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarkers.
  • The poster presentation (G-353) will be held on May 7, 2026, from 5:15 to 7:30 PM CT.
  • Ardelyx is also sponsoring a Peer Exchange session on May 8, 2026, focused on hyperphosphatemia management using XPHOZAH.
  • XPHOZAH is indicated for adults with chronic kidney disease (CKD) on dialysis who have inadequate response or intolerance to phosphate binders.

The big picture

The chronic kidney disease (CKD) patient population represents a significant unmet medical need, with hyperphosphatemia being a common and serious complication. Ardelyx’s XPHOZAH offers a novel mechanism of action, but its success hinges on demonstrating sustained efficacy and managing side effects, particularly diarrhea, within a competitive landscape of existing phosphate binders. The NKF presentation provides a key data point for assessing the drug's real-world impact.

What we're watching

Adoption Rate
The presentation’s reception and subsequent discussion at the NKF meeting will likely influence physician adoption of XPHOZAH as an add-on therapy, particularly given the reported diarrhea side effect.
Competitive Landscape
The data presented will be scrutinized by competitors developing alternative phosphate management solutions, potentially accelerating innovation or consolidation within the market.
Clinical Utility
Continued observation of long-term patient outcomes and biomarker trends will be crucial to validating XPHOZAH’s clinical utility and justifying its cost relative to existing phosphate binder therapies.